Browsing by Author "WEIR, DONALD"
Now showing items 1-5 of 5
-
The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn's disease have autoantibodies to type VII collagen
KELLEHER, DERMOT P; WEIR, DONALD (Nature, 2002)Epidermolysis bullosa acquisita is an autoimmune blistering disease of the skin characterized by IgG autoantibodies against type VII collagen. Systemic diseases are often associated with epidermolysis bullosa acquisita, ... -
Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis
KELLEHER, DERMOT P; WEIR, DONALD (John Wiley, 2002)BACKGROUND: A number of cases of nephrotoxicity have been reported in patients with inflammatory bowel disease taking oral 5-aminosalicylic acid (5-ASA). AIM: To evaluate the effects of 9 months of therapy with mesalazine ... -
Evidence of unmetabolised folic acid in cord blood of newborn and serum of 4-day-old infants
MCPARTLIN, JOSEPH; SCOTT, JOHN MARTIN; WEIR, DONALD (Cambridge University Press, 2007)Oral folic acid above certain threshold doses results in unmetabolised folic acid in serum. This raises a number of public health safety issues, principally the potential to mask pernicious anaemia; more recently the ... -
Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
KELLEHER, DERMOT P; O'BRIAIN, DONAL SEAN; WEIR, DONALD (BMJ, 2000)BACKGROUND: There is concern that the incidence of non-Hodgkin's lymphoma (NHL) will rise with increasing use of immunosuppressive therapy. AIMS: Our aim was to determine the risk of NHL in a large cohort of patients with ... -
Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study
KELLEHER, DERMOT P; O'MORAIN, COLM ANTOINE; WEIR, DONALD (BMJ, 2001)BACKGROUND AND AIMS: The benefit of 5-aminosalicylic acid therapy for maintenance of remission in Crohn's disease is controversial. The primary aim of this study was to evaluate the prophylactic properties of olsalazine ...